Contributions
Abstract: P865
Type: Poster
Abstract Category: Clinical aspects of MS - MS and gender
Background: Multiple sclerosis (MS) is a neurological disease mostly affecting women of childbearing age.
Recent studies suggest that MS may have a negative impact on fertility. In general, decreased ovarian reserve is supposed to be one of the most important factors for fertility impairment.
Anti-Mullerian hormone (AMH) is a peptide hormone that represents a simple widely available measure of ovarian reserve unrelated to the menstrual cycle.
Objective: The purpose of this study was to determine AMH levels in females with relapsing-remitting MS (RRMS) in comparison with healthy volunteers.
Methods: A total of 25 reproductive-age females (among 25-36 years) with RRMS and 24 age matched healthy controls were included in this case control study. In females with MS the median EDSS score was 2.5 points, patients received first-line treatment (glatiramer acetat or interferon beta 1a,1b). The median disease duration was 3.1 years.
An enzymatically amplified two-site immunoassay was used to measure serum AMH level.
Results: Mean AMH level was significantly decreased in females with RRMS (1.1 ng/ml) in comparison with healthy controls (2.3ng/ml) (p< 0.01). In MS group 13 patients (59%) showed very low AMH values (< 0.4 ng/ml) compared to group of healthy controls. In a group of healthy controls very low AMH was diagnosed in 2 patients (9%) only (p< 0.01).
Conclusions: Our data show that decreased ovarian reserve is frequently found in MS patients even in early stages of the disease and may represent one of the underlying mechanisms of fertility impairment in MS.
This study was supported of the Specific University Research Grant, MUNI/A/1072/2015.
Disclosure: Svobodova M: nothing to disclose
Crha I:nothing to disclose
Nekvapilova E:nothing to disclose
Podborska M: nothing to disclose
Vlckova E: nothing to disclose
Srotova I:nothing to disclose
Stourac P: nothing to disclose
Bednarik J:nothing to disclose
Abstract: P865
Type: Poster
Abstract Category: Clinical aspects of MS - MS and gender
Background: Multiple sclerosis (MS) is a neurological disease mostly affecting women of childbearing age.
Recent studies suggest that MS may have a negative impact on fertility. In general, decreased ovarian reserve is supposed to be one of the most important factors for fertility impairment.
Anti-Mullerian hormone (AMH) is a peptide hormone that represents a simple widely available measure of ovarian reserve unrelated to the menstrual cycle.
Objective: The purpose of this study was to determine AMH levels in females with relapsing-remitting MS (RRMS) in comparison with healthy volunteers.
Methods: A total of 25 reproductive-age females (among 25-36 years) with RRMS and 24 age matched healthy controls were included in this case control study. In females with MS the median EDSS score was 2.5 points, patients received first-line treatment (glatiramer acetat or interferon beta 1a,1b). The median disease duration was 3.1 years.
An enzymatically amplified two-site immunoassay was used to measure serum AMH level.
Results: Mean AMH level was significantly decreased in females with RRMS (1.1 ng/ml) in comparison with healthy controls (2.3ng/ml) (p< 0.01). In MS group 13 patients (59%) showed very low AMH values (< 0.4 ng/ml) compared to group of healthy controls. In a group of healthy controls very low AMH was diagnosed in 2 patients (9%) only (p< 0.01).
Conclusions: Our data show that decreased ovarian reserve is frequently found in MS patients even in early stages of the disease and may represent one of the underlying mechanisms of fertility impairment in MS.
This study was supported of the Specific University Research Grant, MUNI/A/1072/2015.
Disclosure: Svobodova M: nothing to disclose
Crha I:nothing to disclose
Nekvapilova E:nothing to disclose
Podborska M: nothing to disclose
Vlckova E: nothing to disclose
Srotova I:nothing to disclose
Stourac P: nothing to disclose
Bednarik J:nothing to disclose